These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24742627)

  • 1. Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice.
    Berman-Booty LD; Thomas-Ahner JM; Bolon B; Oglesbee MJ; Clinton SK; Kulp SK; Chen CS; La Perle KM
    Toxicol Pathol; 2015 Feb; 43(2):186-97. PubMed ID: 24742627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.
    Chiaverotti T; Couto SS; Donjacour A; Mao JH; Nagase H; Cardiff RD; Cunha GR; Balmain A
    Am J Pathol; 2008 Jan; 172(1):236-46. PubMed ID: 18156212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Yeh IT; Reddick RL; Kumar AP
    Prostate; 2009 May; 69(7):755-60. PubMed ID: 19170049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
    J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
    Jain AK; Raina K; Agarwal R
    Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
    Tepaamorndech S; Huang L; Kirschke CP
    Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
    Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
    Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
    Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.
    Mavis CK; Morey Kinney SR; Foster BA; Karpf AR
    Prostate; 2009 Sep; 69(12):1312-24. PubMed ID: 19444856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD; Zakrajsek BA; Hill RE; Liu Q; Reeves JJ; Axford PD; Singer MJ; Reed MW
    Prostate; 2003 Jun; 55(4):308-16. PubMed ID: 12712410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone-rich Kava fraction.
    Tang SN; Zhang J; Jiang P; Datta P; Leitzman P; O'Sullivan MG; Jiang C; Xing C; Lü J
    Mol Carcinog; 2016 Dec; 55(12):2291-2303. PubMed ID: 26840761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-independent prostate cancer progression in the TRAMP model.
    Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
    Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
    Peek EM; Song W; Zhang H; Huang J; Chin AI
    Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
    Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J
    Cancer Res; 2007 Jun; 67(12):5965-75. PubMed ID: 17575167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.
    Huss WJ; Gray DR; Tavakoli K; Marmillion ME; Durham LE; Johnson MA; Greenberg NM; Smith GJ
    Neoplasia; 2007 Nov; 9(11):938-50. PubMed ID: 18030362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice.
    Kalin TV; Wang IC; Ackerson TJ; Major ML; Detrisac CJ; Kalinichenko VV; Lyubimov A; Costa RH
    Cancer Res; 2006 Feb; 66(3):1712-20. PubMed ID: 16452231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
    Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
    Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression.
    Anzo M; Cobb LJ; Hwang DL; Mehta H; Said JW; Yakar S; LeRoith D; Cohen P
    Cancer Res; 2008 May; 68(9):3342-9. PubMed ID: 18451161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.